Creative Biolabs recently participated in the Scientist Solution Vendor Event, presenting comprehensive biotech solutions that could significantly impact precision medicine and oncology research. The company's showcase highlighted advanced CDMO services spanning antibody development, plasmid production, and tumor-infiltrating lymphocyte (TIL) therapy.
The company's booth emphasized a comprehensive approach to biotechnology services, including stable cell line development, upstream and downstream process optimization, and regulatory compliant manufacturing solutions. Particularly noteworthy was their plasmid process development strategy, which ensures high-quality, high-yield production through rigorous validation workflows.
In the oncology domain, Creative Biolabs is pioneering TIL therapy development, integrating tumor resection, lymphocyte isolation, and expansion techniques. Their approach utilizes advanced rapid expansion protocols, leveraging monoclonal antibodies and sophisticated cell cultivation technologies to create patient-specific treatments.
The company is also preparing for a significant gene therapy webinar featuring Dr. Omar Abudayyeh, which will explore emerging technologies in programmable gene editing, cellular perturbation, and artificial intelligence applications in biotechnology.
Creative Biolabs has a robust 2025 event calendar, with planned appearances at prestigious conferences including the NIH Spring Research Vendor Fair, BioPharma Drug Discovery Nexus Conference, World Bispecific Summit, World ADC San Diego, and Antibody Engineering & Therapeutics event.
